

ARTICLE OPEN



Translational Therapeutics

Metformin abrogates *Fusobacterium nucleatum*-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness

Xia-Lu Hong^{1,3}, Ta-Chung Yu^{1,3}, Xiao-Wen Huang^{1,3}, Ji-Lin Wang¹, Tian-Tian Sun¹, Ting-Ting Yan¹, Cheng-Bei Zhou¹, Hui-Min Chen¹, Wen-Yu Su¹, Wan Du¹ and Hua Xiong^{1,2}

© The Author(s) 2022

BACKGROUND: Chemotherapy resistance is the major cause of recurrence in patients with colorectal cancer (CRC). A previous study found that *Fusobacterium (F.) nucleatum* promoted CRC chemoresistance. Additionally, metformin rescued *F. nucleatum*-induced tumorigenicity of CRC. Here, we aimed to investigate whether metformin could revert *F. nucleatum*-induced chemoresistance and explore the mechanism.

METHODS: The role of metformin in *F. nucleatum*-infected CRC cells was confirmed using cell counting kit 8 assays and CRC xenograft mice. Stemness was identified by tumorsphere formation. Bioinformatic analyses were used to explore the regulatory molecules involved in metformin and *F. nucleatum*-mediated regulation of the sonic hedgehog pathway.

RESULTS: We found that metformin abrogated *F. nucleatum*-promoted CRC resistance to chemotherapy. Furthermore, metformin attenuated *F. nucleatum*-stimulated stemness by inhibiting sonic hedgehog signaling. Mechanistically, metformin diminished sonic hedgehog signaling proteins by targeting the MYC/miR-361-5p cascade to reverse *F. nucleatum*-induced stemness, thereby rescuing *F. nucleatum*-triggered chemoresistance in CRC.

CONCLUSIONS: Metformin acts on *F. nucleatum*-infected CRC via the MYC/miR-361-5p/sonic hedgehog pathway cascade, subsequently reversing stemness and abolishing *F. nucleatum*-triggered chemoresistance. Our results identified metformin intervention as a potential clinical treatment for patients with chemoresistant CRC with high amounts of *F. nucleatum*.

British Journal of Cancer (2023) 128:363–374; <https://doi.org/10.1038/s41416-022-02044-6>

BACKGROUND

Colorectal cancer (CRC) incidence and mortality remain high, constituting a major public health burden [1]. Chemotherapy is the most common treatment to reduce tumor growth and inhibit tumor metastasis. 5-fluorouracil (5-Fu) and oxaliplatin are the first-line chemotherapeutic drugs in the treatment of patients with advanced CRC [2, 3]. However, CRC cells usually become resistant to chemotherapeutic agents, leading to tumor recurrence. It has been reported that more than 30% patients receiving surgery for stage II and III colon cancer are resistant to 5-Fu-based adjuvant chemotherapy within 8 years of follow-up [4]. Furthermore, about 50% of patients who were diagnosed with metastatic CRC were resistant to 5-Fu-based chemotherapy and their 5-year survival rate was lower than 15% [5]. Thus, it is necessary to determine the molecular mechanisms of CRC chemoresistance and develop new and effective strategies to improve chemosensitivity.

Chemoresistance of CRC is a complex process resulting from the interplay between intrinsic and extrinsic factors, including gene

regulation, epigenetic modification, hypoxia, and the gut microbiota [6, 7]. Accumulating evidence indicates that the gut microbiota profoundly influences the effect of chemotherapy with three main outcomes: facilitation of drug efficacy; restraint and compromise of anticancer effects; and mediation of toxicity effects [8]. Some bacteria, such as *Lactobacillus johnsonii*, *L. murinus*, and *Bacteroidetes*, promote chemotherapy efficacy [9, 10]. However, some bacteria, such as *F. nucleatum*, a well-known CRC pathogenic factor, drive high chemoresistance [11–14]. Our previous work demonstrated that an increased abundance of *F. nucleatum* contributes to post-chemotherapy recurrence in patients with CRC [15]. As such, this is an important clinical consideration when evaluating conventional chemotherapeutic treatment of patients with CRC with a high amount of *F. nucleatum*. Therefore, a strategy capable of modulating the effects of *F. nucleatum* in the management of CRC is highly desirable. However, to date, the problem of CRC chemoresistance caused by *F. nucleatum* has not been solved. Our previous work pinpointed

¹Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory for Oncogenes and Related Genes; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China. ²Division of Gastroenterology and Hepatology, Ningbo Hangzhou Bay Hospital, 1155 Second Binhai Road, Ningbo 315336, China. ³These authors contributed equally: Xia-Lu Hong, Ta-Chung Yu, Xiao-Wen Huang. email: duwan2017@126.com; huaxiong1979@163.com

that metformin could elicit an antitumor effect by restoring the disordered intestinal microbiota and alleviating *F. nucleatum*-induced colorectal tumorigenesis [16]. Metformin, which has been used widely in type 2 diabetes (T2D) for more than 60 years, has attracted interest in the prevention and treatment of various cancers recently [17–20]. A phase II clinical trial reported a modest efficacy profile of a combination of metformin and 5-Fu in patients with refractory CRC [21]. These raised the possibility that metformin might play a role in treating chemoresistance in patients with CRC with high abundance of *F. nucleatum*. In the current work, we aimed to determine whether and how metformin affects *F. nucleatum*-induced CRC chemoresistance. We found that metformin plays a critical role in abrogating *F. nucleatum*-induced CRC chemoresistance in response to 5-Fu and oxaliplatin through the MYC/miR-361-5p cascade, and subsequently suppression of sonic hedgehog signaling and CRC cell stemness. Our approach might inspire a future combined treatment comprising metformin with chemotherapeutic drugs to managing recurrence in patients with CRC with high amounts of *F. nucleatum*.

METHODS

Cell culture and treatment

Human CRC cell lines with different degrees of differentiation (HT-29, well differentiated; HCT 116, moderately differentiated) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in McCoy's 5A medium (GIBCO, Carlsbad, CA, USA) with 10% (vol/vol) fetal bovine serum (FBS) (GIBCO) at 37 °C in a humidified 5% CO₂ atmosphere. 1 mM metformin (Sigma-Aldrich, St. Louis, MO, USA) was used to treat CRC cells for 24–72 h. *F. nucleatum* at a multiplicity of infection (MOI) of 100 was used to treat CRC cells for 4 h. The miR-361-5p mimics and miR-361-5p inhibitor were transfected into CRC cells using the DharmaFECT transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA). The lentivirus control and lentiviral vectors expressing miR-361-5p inhibitors were purchased from Shanghai OBiO medical biotechnology company (Shanghai, China).

F. nucleatum culture

The *F. nucleatum* strain (ATCC 25586) was obtained from the ATCC. *F. nucleatum* was cultured for 24 h at 37 °C under anaerobic conditions in brain heart infusion (BHI) broth containing hemin, Vitamin K1, K₂HPO₄, and L-Cysteine.

Mouse models

For the xenograft experiments, 4–5-week-old male *Balb/c* nude mice were purchased from the Shanghai Model Organisms Center (Shanghai, China) and housed in specific pathogen-free (SPF) conditions. HCT 116 cells (5×10^6 or 2.5×10^6) with different treatments were suspended in 100 µl of phosphate-buffered saline (PBS) and inoculated subcutaneously into the right axilla of the mice to establish the CRC xenograft model. Six days after subcutaneous injection, mice with xenograft tumors and no significant differences in tumor load were divided into different groups ($n = 5$). *F. nucleatum* (MOI = 100, 100 µl per mouse) were given by multipoint intratumoral injection, twice per week for 2 weeks. Metformin (125 mg/Kg) was administered via gavage every day for two weeks. Chemotherapeutic agents (FOX: 5-Fu 5 mg/Kg + Oxaliplatin 6 mg/Kg) were administered by intraperitoneal injection, twice per week for 2 weeks.

To explore the role of metformin in *F. nucleatum*-induced chemoresistance in vivo, we designed seven groups: (i) Control group; (ii) Metformin group; (iii) *F. nucleatum* group; (iv) FOX group; (v) FOX and metformin group; (vi) FOX and *F. nucleatum* group; (vii) FOX, *F. nucleatum*, and metformin group.

To explore whether metformin reversed *F. nucleatum*-mediated chemoresistance via miR-361-5p, we generated stable miR-361-5p knock-down HCT 116 cells by transducing lentiviruses expressing miR-361-5p inhibitors. We designed four groups: (i) FOX group; (ii) FOX and *F. nucleatum* group; (iii) FOX, *F. nucleatum* and metformin group; (iv) FOX, *F. nucleatum*, metformin, and miR-361-5p inhibitor group.

The length and width of the tumors were measured every 2–3 days. Tumor volume (mm³) was calculated as (length × width²) / 2. If the tumor

volume exceeded 2000 mm³, the mouse was killed for welfare reasons. After 2 weeks, the mice were killed humanely and subcutaneous tumors were collected for subsequent analysis of sonic hedgehog (SHH), GLI family zinc finger 1 (GLI1), SRY box transcription factor 2 (SOX2) and Nanog homeobox (NANOG) expression. Mouse experiments were conducted according to the guidelines approved by the Institutional Animal Care and Use Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University.

RNA extraction and quantitative real-time PCR

Total RNA was extracted from HT-29 and HCT 116 cells using the Trizol reagent (Takara, Shiga, Japan). For the analysis of mRNA and primary microRNA (pri-miRNA), 1 µg of total RNA was reverse transcribed into first-strand cDNA using a PrimeScript RT Reagent Kit (Takara). For the miRNAs, 500 ng of total RNA was reverse transcribed using Mir-X™ TM miRNA First-Strand Synthesis Kit (Takara). The quantitative real-time PCR step was conducted using TB Green Premix Ex Taq™ II (Takara) on an ABI StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The relative gene expression was calculated using 2^{-ΔΔCt} method and expressed as the fold change [22]. *ACTB* (encoding β-actin) and *U6* were used, respectively, as endogenous references for the mRNA, pri-miRNA, and miRNA assays. The mRNA primers used in real-time PCR are shown in Table 1. The miRNA primers and pri-miRNA primers were purchased from GeneCopoeia (Rockville, MD, USA).

Western blotting

Proteins (60 µg) were separated using 8% or 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA), and incubated with primary antibodies overnight. The membranes were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:3000, KangChen, Shanghai, China) and the signals were visualized using an enhanced luminescence (ECL) Kit (Thermo Fisher Scientific). The following commercial antibodies were used: anti-SHH (Cell Signaling Technology, Danvers, MA, USA), anti-GLI1 (Cell Signaling Technology), anti-SOX2 (Cell Signaling Technology), anti-NANOG (Cell Signaling Technology), anti-MYC antibody (Abcam, Cambridge, UK) and anti-β-actin (Cell Signaling Technology). All antibodies were used at a dilution of 1:1000.

Tumorsphere formation assay

CRC cells were exposed to *F. nucleatum* (MOI = 100) for 4 h. Then, the medium containing *F. nucleatum* was replaced with McCoy's 5A medium supplemented with 10% FBS. After 24 h, HT-29 and HCT 116 cells were seeded in low-adherent 96-well plates at a density of 400 cells per well in serum-free tumorsphere medium with or without 1 mM metformin. The tumorsphere medium consisted of Dulbecco's Modified Eagle Medium/F12 (GIBCO) supplemented with necessary growth factors [23]. After a 4-day

Table 1. List of the RT-PCR primers used in this study.

Primer name	Sequence (5'-3')
GLI1 Forward	GGGTGCCGGAAGTCATACTC
GLI1 Reverse	GCTAGGATCTGTATAGCGTTTGG
SHH Forward	CAGTGGACATCACCACGTCT
SHH Reverse	CCGAGTCTCTGCTTTCACC
SOX2 Forward	TGGACAGTTACGCGCACAT
SOX2 Reverse	CGAGTAGGACATGCTGTAGGT
NANOG Forward	ATAACCTTGCGTCCGTCTC
NANOG Reverse	GATGCAGCAAATACGAGACCT
HES1 Forward	TGAGCACAGACCCAAGTGTG
HES1 Reverse	CCTCGGTATTAACGCCCTCG
TCF1 Forward	TGCACATGCAGCTATACCCAG
TCF1 Reverse	TGGTGGATTCTGGTGCTTTTC
β-actin Forward	CTGGGCCTCGTCCCCACATA
β-actin Reverse	CTGGGCCTCGTCCCCACATA

incubation, the tumorspheres were counted under a light microscope and their size were quantified using Image J software (NIH, Bethesda, MD, USA).

Cell Counting Kit-8 (CCK-8) assay

CRC cells were seeded at 2500 cells per well into 96-well plates with 100 μ l of medium. After attachment, HT-29 and HCT 116 cells were treated with different interventions for 72 h. Then, 10 μ l of CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each well at specific times and the absorbance value at 450 nm was measured after 2 h of incubation.

Data acquisition

For the analysis of cancer stem cell pathways, the data and sample information of GSE102573, GSE90944, and GSE67342 were downloaded from the Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>). GSE102573 comprises the expression profile of Caco-2 cells infected with *F. nucleatum* or not. GSE90944 comprises RNA sequencing (RNA-seq) data of HT-29 cells with or without *F. nucleatum* treatment. GSE67342 comprises expression data of LoVo cells treated by metformin. The single-sample gene set enrichment analysis (ssGSEA) score was calculated using Gene Set Variation Analysis (GSVA) in the R package with the chemical and genetic perturbations gene set collection (MSigDB C2 CGP; 3358 gene sets available) [24]. Differential expression analysis was conducted using the R package Limma and an adjusted (Bonferroni–Holm method) two-tailed $P < 0.05$ was considered statistically significant.

For the analysis of metformin-regulated genes, we used the dataset GSE67342, which includes gene expression of LoVo cells treated by metformin. An adjusted $P < 0.1$ was considered statistically significant.

Dual luciferase assay

HT-29 and HCT 116 cells were co-transfected with 100 ng of the reporter plasmids and 10 ng of the pRL-TK-Renilla-luciferase plasmids using the FuGene transfection reagent (Promega, Madison, WI). At 6 h after transfection, the medium was replaced and cells were treated with metformin and/or *F. nucleatum*. At 72 h after transfection, dual luciferase activities were estimated using a Dual-Luciferase Assay Kit (Promega) according to the manufacturer's instructions. Each transfection was performed in four complex wells and repeated twice.

Statistical analysis

All data analyses were performed using GraphPad Prism version 7 (GraphPad Inc., La Jolla, CA, USA). Data are expressed as the mean \pm standard deviation (SD) or the mean \pm standard error of the mean (SEM). The differences between experimental groups were analyzed using an unpaired t test. In the figures, asterisks denote statistical significance (n.s., not significant, $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$).

RESULTS

Metformin abolishes *F. nucleatum*-induced chemoresistance in vivo and in vitro

To explore the role of metformin in *F. nucleatum*-induced chemoresistance, we initially verified metformin's effect on CRC cell proliferation. After treating CRC cells with different concentration of metformin, we observed that 500 μ M and 1 mM metformin did not affect the proliferation of HT-29 cells (Fig. S1a) or HCT 116 cells (Fig. S1b). However, 5 mM and 10 mM metformin inhibited the proliferation in both CRC cell lines (Fig. S1a, b). Importantly, 1 mM metformin is approximately the physiological concentration in the colon of patients taking this drug [25]. In addition, our previous work demonstrated that an MOI of 100 of *F. nucleatum* had no effect on CRC cell proliferation but could trigger CRC cell chemoresistance [15]. Therefore, we chose 100 MOI of *F. nucleatum* and 1 mM metformin for subsequent experiments. HT-29 and HCT 116 cells were pre-infected with *F. nucleatum* for 4 h and then treated with a gradient concentration of 5-Fu or oxaliplatin in the presence of 1 mM metformin. In line with our previous observations, *F. nucleatum* decreased the cytotoxicity of 5-Fu and oxaliplatin in HT-29 cells (Fig. 1a, b) and HCT 116 cells

(Fig. 1c, d), respectively, after 72 h. These results suggest that *F. nucleatum* promotes chemoresistance of CRC cells. Interestingly, metformin markedly enhanced the cytotoxicity of 5-Fu and oxaliplatin in *F. nucleatum*-infected HT-29 cells (Fig. 1a, b) and HCT 116 cells (Fig. 1c, d), but not in *F. nucleatum*-free HT-29 cells and HCT 116 cells. Thus, metformin could abolish *F. nucleatum*-induced CRC chemoresistance in vitro.

To further verify this conclusion, HCT 116 cells were inoculated into *Balb/c* nude mice, followed by treatment with metformin (125 mg/Kg/d), *F. nucleatum*, chemotherapeutic agents (FOX: 5-Fu 5 mg/Kg + Oxaliplatin 6 mg/Kg) and other manipulations. We observed comparable tumor growth (Fig. 1e), tumor volumes (Fig. 1f), and tumor weights (Fig. 1g) in the control, metformin, and *F. nucleatum* groups. As expected, tumor growth (Fig. 1e), tumor volumes (Fig. 1f), and tumor weights (Fig. 1g) were significantly decreased by FOX treatment, and this decrease was blocked by *F. nucleatum* infection. These data further demonstrated that *F. nucleatum* participated in CRC chemoresistance. Remarkably, *Balb/c* nude mice treated with *F. nucleatum* plus 1 mM metformin exhibited a better response to FOX, with impaired tumor growth, reduced tumor volumes, and lower tumor weights, when compared with the *F. nucleatum* plus FOX group (Fig. 1e–g). Collectively, these data supported the view that metformin reverses *F. nucleatum*-induced CRC chemoresistance.

Metformin attenuates *F. nucleatum*-induced chemoresistance by inhibiting CRC cell stemness

We next explored the detailed mechanisms by which metformin abolished *F. nucleatum*-induced CRC chemoresistance. Given the crucial role of stemness in cancer chemoresistance [26], we hypothesized that metformin might rescue *F. nucleatum*-induced chemoresistance through inhibition of cancer stemness. To test this assumption, we performed bioinformatic analysis to predict the regulation of metformin and *F. nucleatum* in cancer stem cell pathways. We collected the gene expression data for CRC cells treated with metformin or *F. nucleatum* from GEO. Subsequently, ssGSEA showed that *F. nucleatum* upregulated cancer stem cell pathways, whereas metformin downregulated cancer stem cell pathways (Fig. 2a). Based on this data, we speculated that metformin might inhibit *F. nucleatum*-stimulated CRC stemness. Consistently, the tumorsphere formation assay showed that *F. nucleatum* increased the number and diameter of tumorspheres in both HT-29 cells (Fig. 2b) and HCT 116 cells (Fig. 2c). By contrast, metformin significantly inhibited the number and diameter of tumorspheres in *F. nucleatum*-stimulated HT-29 cells (Fig. 2b) and HCT 116 cells (Fig. 2c), but not in *F. nucleatum*-free cells.

In support of this data, we detected the expression of stemness markers after metformin and *F. nucleatum* treatment. NANOG and SOX2 are two important markers of stemness. *F. nucleatum* enhanced the mRNA and protein expression levels of SOX2 and NANOG in HT-29 and HCT 116 cells (Fig. 2d–f). Metformin abolished *F. nucleatum*-induced upregulation of SOX2 and NANOG at both the mRNA (Fig. 2d, e) and protein (Fig. 2f) levels. In line with the above results, western blotting analysis also showed that metformin downregulated *F. nucleatum*-stimulated SOX2 and NANOG expression in FOX-treated subcutaneous xenograft mice (Fig. 2g). Taken together, our data indicated that metformin attenuates *F. nucleatum*-induced chemoresistance by inhibiting CRC cell stemness.

Metformin rescues *F. nucleatum*-induced stemness by inhibiting the sonic hedgehog pathway

We next examined how metformin rescued *F. nucleatum*-induced stemness in CRC cells. Notch, Wnt/ β -catenin, and sonic hedgehog signaling pathways are known to play a decisive role in tumor stemness via regulating SOX2 and NANOG expression [27]. We hypothesized that Notch, Wnt/ β -catenin, or sonic hedgehog signaling pathways were involved in the recovery effect of




Fig. 1 Metformin suppresses *F. nucleatum*-induced chemoresistance in vivo and in vitro. **a, b** Cell proliferation was detected by CCK-8 assays in HT-29 cells. HT-29 cells were co-cultured with *F. nucleatum* or treated with 1 mM metformin, and different concentration of 5-Fu (**a**) and Oxaliplatin (**b**); unpaired *t*-test. **c, d** Cell proliferation was detected by CCK-8 assays in HCT 116 cells. HCT 116 cells were co-cultured with *F. nucleatum* or treated with 1 mM metformin, and different concentration of 5-Fu (**c**) and Oxaliplatin (**d**); unpaired *t*-test. **e** Representative data of tumors in mice under different conditions. **f, g** Statistical analysis of tumor volumes (**f**) and weights (**g**) in the different groups, $n = 5/\text{group}$; values indicate mean \pm standard error of the mean (SEM); unpaired *t*-test. n.s., $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

metformin in *F. nucleatum*-induced stemness. To test this hypothesis, we evaluated these three signaling pathways by testing the expression of critical transcription factors individually, including SHH (sonic hedgehog pathway), GLI1 (sonic hedgehog pathway), Transcription factor 1 (TCF1) (Wnt pathway), and Hes family BHLH transcription factor 1 (HES1) (Notch pathway). *F. nucleatum* enhanced the mRNA expression of SHH, GLI1, TCF, and HES1 in HT-29 cells (Fig. 3a and Fig. S2a) and HCT 116 cells (Fig. 3b and Fig. S2b). This indicated *F. nucleatum* activates these three pathways. To our surprise, metformin reduced the mRNA expression of SHH and GLI1 in *F. nucleatum*-infected HT-29 cells (Fig. 3a) and HCT 116 cells (Fig. 3b), but not in *F. nucleatum*-free CRC cells. Consistently, western blotting also showed metformin reduced SHH and GLI1 protein levels (Fig. 3c). By contrast,

metformin could not downregulate the expression of TCF1 and HES1 in *F. nucleatum*-infected CRC cells (Fig. S2a, b). These data implied that the sonic hedgehog pathway might be involved in the metformin-mediated downregulation of *F. nucleatum*-induced stemness. In accordance with these results, CRC xenograft mice treated with FOX also showed that metformin diminished *F. nucleatum*-stimulated SHH and GLI1 protein levels (Fig. 3d). These data indicated that metformin inhibits *F. nucleatum*-induced stemness by inhibiting the sonic hedgehog pathway.

MiR-361-5p inhibits the sonic hedgehog signaling pathway and stemness

Next, we conducted luciferase assays to investigate the molecular mechanism by which metformin and *F. nucleatum* control sonic




Fig. 2 Metformin attenuates *F. nucleatum*-induced stemness in CRC cells. **a** ssGSEA analysis was conducted to show the alteration of stemness-related pathways in colorectal cancer cells treated with *F. nucleatum* or metformin. **b, c** Tumorspheres were observed by light microscopy in HT-29 (**b**) and HCT 116 (**c**) cells co-cultured with *F. nucleatum* or treated with 1 mM metformin. The number and size of tumorspheres was quantified in the right panel. Scale bar, 400 μm . **d, e** Real-time PCR was performed on stemness marker expression in HT-29 (**d**) and HCT 116 (**e**) cells co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h; unpaired *t* test. **f** Western blotting was performed on stemness marker expression in HT-29 and HCT 116 cells co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h. **g** Western blotting was performed to detect stemness-related proteins in xenograft tumors after different treatments. n.s., $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.




Fig. 3 Metformin rescues *F. nucleatum*-induced stemness by inhibiting sonic hedgehog pathway. **a, b** Real-time PCR was performed to evaluate *SHH* and *GLI1* expression in HT-29 (**a**) and HCT 116 (**b**) cells co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h; unpaired *t* test. **c** *SHH* and *GLI1* levels were detected by western blotting in HT-29 and HCT 116 cells. The cells were co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h. **d** Western blotting was performed to detect sonic hedgehog pathway-related proteins in xenograft tumors after different treatments. n.s., $P > 0.05$; *** $P < 0.001$; **** $P < 0.0001$.

hedgehog signaling. When the SHH ligand binds to Patched 1 (PTCH1) at the cell membrane, GLI1 is accumulated and activated. GLI1 is the final transcriptional effector and its expression reflects the activation of sonic hedgehog signaling [28]. Thus, we constructed the recombinant luciferase reporter plasmid pGL3-GLI1, containing the promoter region of *GLI1* (–979 to 33 nts) [29]. Luciferase assays showed that both *F. nucleatum* and metformin had no effect on the transcriptional activity of pGL3-GLI1 in HCT 116 cells (Fig. S3a). This result suggests that the regulation of *GLI1* by metformin and *F. nucleatum* is not dependent on the direct transcriptional modulation of the *GLI1* promoter. Therefore, we sought to determine if metformin and *F. nucleatum* regulated the *GLI1* expression at the post-transcriptional level.

MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression [30]. We hypothesized that dysregulated miRNAs might be involved in metformin- and *F. nucleatum*-regulated *GLI1*. To test this hypothesis, we identified *F. nucleatum*-related miRNAs from two studies [15, 31]. *F. nucleatum* appeared to regulate 262 miRNAs significantly (Fig. 4a). Next, we used the bioinformatic tool, TargetScan (<http://www.targetscan.org>) to identify potential miRNAs that might regulate *GLI1*. Seventy-four potential *GLI1*-regulatory miRNAs were found (Fig. 4a). After overlapping these potential *GLI1*-regulatory miRNAs with the 262 *F. nucleatum*-related miRNAs, we identified six miRNAs (miR-361-5p, miR-509-3-5p, miR-509-5p, miR-103b, miR-4496, and miR-616-3p) that might regulate *GLI1* (Fig. 4a).

We validated whether these six miRNAs are regulated by metformin and *F. nucleatum* using real-time PCR. The results showed that 1 mM metformin alone had no regulatory effect on the six miRNAs (Fig. 4b, c and Fig. S3b, c). Interestingly, only miR-361-5p was significantly downregulated by *F. nucleatum* and this downregulation could be reverted by 1 mM metformin in both HT-29 (Fig. 4b) and HCT 116 cells (Fig. 4c). Although *F. nucleatum* inhibited miR-616-3p expression, the decreased miR-616-3p expression could not be rescued by 1 mM metformin in either CRC cell line (Fig. S3b, c). The other miRNAs were not significantly regulated by either *F. nucleatum* or metformin (Fig. S3b, c). Thus, these data implied that miR-361-5p might contribute to the


downregulation of sonic hedgehog signaling in response to 1 mM metformin in *F. nucleatum*-infected CRC cells.

We next examined whether miR-361-5p could suppress sonic hedgehog signaling and stemness in CRC cells. Targetscan was used to predict the binding site of miR-361-5p in the 3' untranslated region (UTR) of *GLI1*. Position 163–184 of the *GLI1* 3' UTR was identified (Fig. 4d). To verify whether the 3' UTR of *GLI1* mRNA was a functional target of miR-361-5p, we performed dual luciferase reporter gene assays. The 3' UTR sequences of *GLI1* (3' UTR wild-type, WT) and the mutant 3' UTR sequences of *GLI1* (3' UTR mutant, MUT) were cloned into a luciferase reporter vector, separately (Fig. 4d). The dual luciferase assay demonstrated that miR-361-5p mimics suppressed the luciferase activity and miR-361-5p inhibitors elevated the luciferase activity in HCT 116 cells transfected with the WT *GLI1* reporter plasmid, but not with the MUT reporter plasmid (Fig. 4e). These findings indicated that *GLI1* is the specific target of miR-361-5p.

Then, to assess the function of miR-361-5p on the sonic hedgehog pathway and stemness, we transfected miR-361-5p mimics and inhibitors into HT-29 and HCT 116 cells, separately. Overexpression of miR-361-5p decreased the expression levels of SHH, *GLI1*, and NANOG at both the mRNA and protein level. By contrast, inhibition of miR-361-5p increased the expression of SHH, *GLI1*, and NANOG in HT-29 cells (Fig. 4f, g) and HCT 116 cells (Fig. 4h, i). In addition, the number and size of tumorspheres were reduced in the miR-361-5p overexpressing HT-29 (Fig. 4j and Fig. S3d) and HCT 116 cells (Fig. 4k and Fig. S3e). Thus, these data support the view that miR-361-5p suppresses the sonic hedgehog pathway and subsequently inhibits CRC cell stemness.

Metformin reverts miR-361-5p in *F. nucleatum*-infected CRC cells via inhibiting MYC

We next investigated the potential mechanisms responsible for the upregulation of miR-361-5p by metformin in *F. nucleatum*-infected cells. MiRNA genes are transcribed into primary miRNA (pri-miRNA) transcripts; therefore, we first detected pri-miR-361 expression using real-time PCR. *F. nucleatum* inhibited the expression of pri-miR-361 in HT-29 and HCT 116 cells (Fig. 5a, b). Metformin increased the expression of pri-miR-361 in *F.*



nucleatum-infected HT-29 and HCT 116 cells, but not in *F. nucleatum*-free cells (Fig. 5a, b). These data indicated that metformin and *F. nucleatum* might regulate the transcription of miR-361-5p. To identify potential transcription factors of miR-361-

5p, we employed the TransmiR v2.0 database (<http://www.cuilab.cn/transmirwas>) and predicted 48 transcription factors that might govern the expression of miR-361-5p directly (Fig. 5c). To explore metformin-regulated transcription factors, we analyzed

Fig. 4 miR-361-5p inhibited the sonic hedgehog signaling pathway and stemness. **a** Schematic illustration of the target miRNA candidate screening process. **b, c** Expression of miR-361-5p was quantified by real-time PCR in HT-29 (**b**) and HCT 116 cells (**c**). The cells were co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h; unpaired *t* test. **d** The predicted binding sequences for miR-361-5p within the human *GLI1* 3' UTR. Seed sequences are highlighted. **e** Luciferase activity was measured in HCT 116 cells transfected with miR-361-5p mimics or control mimics, miR-361-5p inhibitors or control inhibitors for 72 h. The luciferase reporters expressing wild-type or mutant human *GLI1* 3' UTRs were used; unpaired *t* test. **f, g** Real-time PCR (**f**) and western blotting (**g**) were performed in HT-29 cells to detect the expression levels of SHH, GLI1, and NANOG after transfection with miR-361-5p mimics or inhibitors for 48 h; unpaired *t* test. **h, i** Real-time PCR (**h**) and western blotting (**i**) were performed in HCT 116 cells to detect the expression levels of SHH, GLI1, and NANOG after transfection with miR-361-5p mimics or inhibitors for 48 h; unpaired *t* test. **j, k** Tumorspheres were observed by light microscopy in HT-29 (**j**) and HCT 116 (**k**) cells to detect the tumorsphere formation capability after transfection with miR-361-5p mimics; the number of the tumorspheres were quantified in the right panel. Scale bar, 400 μ m; unpaired *t* test. n.s., $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

microarray data to compare gene expression profiles of metformin-treated LoVo cells and control. After application of the filtering criterion (adjusted $P < 0.1$), a total of 560 down-regulated genes and 292 upregulated genes were detected (Fig. 5c). Four transcription factors (*MYC*, *FOS*, *FOXF2*, and *JUN*) were identified after overlapping the 48 potential transcription factors and the metformin-regulated genes (Fig. 5c). Among these four transcription factor genes, *MYC* was the most significantly downregulated gene by metformin and was well characterized to bind to miRNA promoters directly [32].

To determine whether *MYC* contributed to the recovery effect of metformin in *F. nucleatum*-inhibited miR-361-5p, we first detected the expression of *MYC* in CRC cells treated with metformin and *F. nucleatum*. The levels of the *MYC* transcript (Fig. 5d, e) and protein (Fig. 5f) were enhanced in response to *F. nucleatum* infection in HT-29 cells and HCT 116 cells. Metformin reduced the levels of *MYC* mRNA (Fig. 5d, e) and protein (Fig. 5f) in *F. nucleatum*-infected HT-29 cells and HCT 116 cells, but not in *F. nucleatum*-free CRC cells. Moreover, metformin failed to upregulate pri-miR-361 and miR-361-5p when *MYC* was overexpressed in *F. nucleatum*-infected HT-29 cells (Fig. 5g) and HCT 116 cells (Fig. 5h). Collectively, the data suggested that metformin decreases miR-361-5p transcription in *F. nucleatum*-infected cells by inhibiting *MYC*.

Metformin reverses *F. nucleatum*-induced stemness and chemoresistance via the miR-361-5p/ sonic hedgehog axis

To determine whether miR-361-5p regulates *F. nucleatum*-mediated sonic hedgehog pathway and CRC stemness, miR-361-5p mimics or inhibitors were transfected in *F. nucleatum*-treated CRC cells. Western blotting analysis revealed that miR-361-5p mimics decreased SHH, GLI1, and NANOG protein levels in HT-29 (Fig. 6a) and HCT 116 cells (Fig. 6b) cultured with *F. nucleatum*. Consistent with these results, a loss-of-function study showed miR-361-5p inhibitors increased the levels of SHH, GLI1, and NANOG in HT-29 (Fig. 6a) and HCT 116 cells (Fig. 6b), which presented the same effect as *F. nucleatum*. In addition, the number and size of tumorspheres stimulated by *F. nucleatum* were reduced in miR-361-5p overexpressing HT-29 cells (Fig. 6c) and HCT 116 cells (Fig. 6d). Thus, these data supported the view that *F. nucleatum* activates the sonic hedgehog signaling pathway and CRC stemness via the selective loss of miR-361-5p.

To address whether metformin blocked *F. nucleatum*-stimulated sonic hedgehog pathway and CRC stemness in a miR-361-5p-dependent manner, miR-361-5p mimics or 1 mM metformin were used to treat *F. nucleatum*-infected CRC cells. Similar to metformin, the miR-361-5p mimics decreased the SHH, GLI1, and NANOG levels stimulated by *F. nucleatum* in HT-29 cells (Fig. 6e) and HCT 116 cells (Fig. 6f). MiR-361-5p inhibitors abolished the inhibitory effects of metformin on SHH, GLI1, and NANOG levels in *F. nucleatum*-infected HT-29 cells (Fig. 6e) and HCT 116 cells (Fig. 6f). Consistently, tumorsphere formation assays showed that the miR-361-5p mimics repressed the number and size of tumorspheres in *F. nucleatum*-infected HT-29 cells (Fig. 6g) and HCT 116 cells (Fig. 6h). Besides, miR-361-5p inhibitors significantly blocked the

inhibitory effects of metformin on tumorsphere numbers in *F. nucleatum*-stimulated cells (Fig. S3f).

To further assess whether metformin blocked *F. nucleatum*-stimulated chemoresistance in a miR-361-5p-dependent manner, we established stable miR-361-5p knockdown HCT 116 cells by transducing lentiviruses expressing miR-361-5p inhibitors. We then created subcutaneous tumor models via inoculation of the stable miR-361-5p knockdown HCT 116 cells into nude mice, followed by treatment with chemotherapeutic agents, *F. nucleatum*, and metformin. As expected, metformin reversed *F. nucleatum*-induced chemoresistance in control HCT 116 cells (Fig. 6i–k). However, the rescue effect of metformin in *F. nucleatum*-stimulated chemoresistance was abrogated by the miR-361-5p inhibitors in vivo, as shown by the lack of decrease in tumor growth (Fig. 6i), tumor volumes (Fig. 6j), and tumor weights (Fig. 6k). Altogether, we reasoned that metformin acts on *F. nucleatum*-infected CRC via the *MYC*/miR-361-5p cascade, which downregulates the sonic hedgehog signaling pathway, subsequently reversing CRC stemness and abolishing *F. nucleatum*-triggered chemoresistance (Fig. S4).

DISCUSSION

Chemotherapeutic agents, such as 5-Fu and oxaliplatin, remain the backbone of treatment for patients with CRC; however, the development of chemoresistance is the major cause for treatment failure. Cancer chemoresistance is a complex process and results from the interplay between intrinsic and extrinsic factors. Tumors with genetic and epigenetic alterations are critical for the CRC chemotherapeutic response [6]. Recent studies also showed that the gut microbiota controlled the response to chemotherapy by modulating the tumor microenvironment [33]. *F. nucleatum* abundance is associated with the properties of CRC, such as tumorigenesis, development, metastasis, and recurrence [34]. Through a combination of bioinformatic analyses, biological experiments, in vivo models, and clinical studies, we demonstrated that abnormal proliferation of *F. nucleatum* led to CRC chemoresistance and recurrence [15]. Given that broad spectrum antibiotics have a negative effect on the healthy intestinal microbiota, and no *F. nucleatum*-specific antimicrobial agent has been discovered, chemoresistance caused by *F. nucleatum* remains a thorny problem in the clinic [35]. Therefore, it is necessary to develop a safe and effective approach to eliminate chemoresistance caused by *F. nucleatum*.

Based on our previous work showing that metformin could attenuate *F. nucleatum*-induced tumorigenesis [16], we further explored the effect of metformin on *F. nucleatum*-induced chemoresistance. To our surprise, metformin abrogated *F. nucleatum*-induced CRC chemoresistance in CRC cells and xenograft mice. However, how metformin affects *F. nucleatum*-mediated chemoresistance was unknown. A distinct tumor cell subpopulation with stemness, known as the cancer stem cell population, exists in cancers, which mediates chemoresistance and metastatic progression [36, 37]. The use of cancer stemness inhibitors, such as napabucasin, can overcome chemoresistance in





Fig. 5 Metformin reverts miR-361-5p in *F. nucleatum*-infected CRC cells via inhibiting MYC. **a, b** Real-time PCR was performed in HT-29 cells (**a**) and HCT 116 (**b**) cells to detect the expression of pri-miR-361. The cells were co-cultured with *F. nucleatum* or treated with 1 mM metformin for 24 h; unpaired *t* test. **c** Venn diagram showing the candidate transcription factor screening process. **d, e** Real-time PCR was performed to evaluate *MYC* expression in HT-29 (**d**) and HCT 116 (**e**) cells treated with 1 mM metformin, *F. nucleatum*, and *F. nucleatum* plus 1 mM metformin for 24 h. **f** *MYC* levels were detected by western blotting in HT-29 and HCT 116 cells. The cells were co-cultured with *F. nucleatum* and/or treated with 1 mM metformin for 24 h. **g, h** Real-time PCR was performed to detect pri-miR-361 and miR-361-5p expression in HT-29 (**g**) and HCT 116 (**h**) cells co-cultured with *F. nucleatum* after *MYC* plasmid transfection, and subsequently treated with or without 1 mM metformin for 24 h. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

human cancers [38–40]. Emerging evidence supports the view that bacterial infections, such as *Enterococcus faecalis*, nonpathogenic *E. coli*, and Enterotoxigenic *Bacteroides fragilis*, might stimulate cancer cell stemness via upregulated expression of stemness markers [41–43]. Our bioinformatic studies demonstrated that a stemness-related pathway is enriched in the modulation of metformin and *F. nucleatum* in CRC cells. Indeed, the effect of metformin depends on the specific regulation of stemness in *F. nucleatum*-infected CRC cells. Accordingly, metformin decreased the expression of stemness-related proteins, SOX2 and NANOG, and inhibited tumorsphere formation in CRC cells co-

cultured with *F. nucleatum*. Thus, we concluded that metformin attenuates *F. nucleatum*-induced chemoresistance by inhibiting stemness in CRC cells. These data might explain why metformin recovers chemosensitivity in *F. nucleatum*-infected CRC cells and xenograft mice.

We dissected the mechanisms by which metformin regulates *F. nucleatum*-induced stemness in CRC cells. Aberrant activity of the sonic hedgehog pathway has been linked to stem cell self-renewal and chemoresistance in variety of solid neoplasms [44]. We demonstrated that sonic hedgehog signaling is a bridge connecting metformin- and *F. nucleatum*-modulated stemness and



chemoresistance. Metformin abolishes *F. nucleatum*-stimulated stemness and subsequently chemoresistance by selectively suppressing sonic hedgehog signaling. Furthermore, metformin and *F. nucleatum* do not affect the transcription of *GLI1*, which

encodes the key effector of the sonic hedgehog pathway. Given that miRNAs are critical post transcriptional regulators [30], our bioinformatic and functional studies revealed miR-361-5p targets *GLI1* and inhibits sonic hedgehog signaling and stemness. In

Fig. 6 Metformin reverses *F. nucleatum*-induced stemness and chemoresistance via the miR-361-5p/sonic hedgehog axis. **a, b** HT-29 (**a**) and HCT 116 (**b**) cells were transfected with mimics or inhibitors of miR-361-5p. After culturing with *F. nucleatum* for 24 h, SHH, GLI1 and NANOG levels were detected by western blotting. **c, d** Tumorspheres were observed by light microscopy in HT-29 (**c**) and HCT 116 (**d**) cells transfected with miR-361-5p mimics, and then co-cultured with *F. nucleatum*. The number and size of the tumorspheres were quantified in the lower panel. Scale bar, 400 μ m; unpaired *t* test. **e, f** Western blotting was performed to detect the levels of SHH, GLI1, and NANOG. After transfection with mimics or inhibitors of miR-361-5p, HT-29 (**e**) and HCT 116 (**f**) cells were treated with 1 mM metformin in the presence of *F. nucleatum* for 24 h. **g, h** After transfection with miR-361-5p mimics, HT-29 (**g**) and HCT 116 (**h**) cells were treated with 1 mM metformin in the presence of *F. nucleatum*. Tumorspheres were observed by light microscopy in HT-29 (**g**) and HCT 116 (**h**) cells. The number and size of the tumorspheres were quantified in the right panel. Scale bar, 400 μ m; unpaired *t* test. **i** Representative data of the tumors in mice under different conditions. **j, k** Statistical analysis of tumor volumes (**j**) and weights (**k**) in the different groups, $n = 5/\text{group}$; unpaired *t* test. Values indicate mean \pm standard error of the mean (SEM); unpaired *t*-test. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

addition, metformin reverses *F. nucleatum*-stimulated stemness, sonic hedgehog signaling and chemoresistance in a miR-361-5p-dependent manner. In line with this notion, we found that metformin decreases miR-361-5p transcripts in *F. nucleatum*-infected cells by downregulating MYC expression. Our data suggested that metformin reverses *F. nucleatum*-induced stemness by inhibiting the MYC/miR-361-5p/sonic hedgehog signaling axis, and then biologically and mechanistically reverting CRC chemoresistance induced by *F. nucleatum*.

In addition to its biological importance, our work might be relevant in the clinical management of patients with CRC. The abundance of *F. nucleatum* is associated with the risk of CRC chemoresistance and recurrence; therefore, combining conventional chemotherapeutic regimens with metformin might be an effective strategy to reverse CRC chemoresistance in patients with high amounts of *F. nucleatum*. Our results highlighted the need for a clinical trial of metformin as a potential treatment in *Fusobacterium*-associated CRC chemoresistance. Furthermore, an important question raised by our data is whether metformin directly affects *F. nucleatum*. It has been reported that metformin exerts its hypoglycemic benefits partly through alteration of the abundance of certain members of the gut microbiota, such as *Bacteroides fragilis* and *Akkermansia muciniphila* [45–48]. Researchers also found that metformin could regulate microbial folate and methionine metabolism, which is required for bacterial growth [46, 49]. These provide the possibility that patients with CRC might benefit from the direct modulation of metformin on *F. nucleatum*. In addition to the details of the mechanisms by which metformin affects *F. nucleatum*-induced host responses, we will explore the direct effect of metformin on *F. nucleatum* colonization and dissemination in a future study.

Our results provide a foundation for the metformin–gut microbiota–host response network in CRC. This network regulation mode might be a direction for meaningful basic and translational medicine research in the future.

DATA AVAILABILITY

Previously published data sets were available in GEO under accession code GSE102573, GSE90944, and GSE67342.

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70:7–30.
- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N. Engl J Med*. 2004;350:2343–51.
- Messersmith WA. Systemic management of colorectal cancer. *J Natl Compr Canc Netw*. 2017;15:699–702.
- Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol*. 2009;27:872–7.
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-

line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet*. 2000;355:1041–7.

- Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. *Pharm Ther*. 2020;206:107447.
- Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. *Nat Rev Cancer*. 2017;17:271–85.
- Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nat Rev Gastroenterol Hepatol*. 2017;14:356–65.
- Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science*. 2013;342:971–6.
- Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015;350:1079–84.
- Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe*. 2013;14:207–15.
- Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe*. 2013;14:195–206.
- Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nat Rev Gastroenterol Hepatol*. 2019;16:690–704.
- Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, et al. *Fusobacterium nucleatum* promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. *J Exp Clin Cancer Res*. 2019;38:14.
- Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. *Fusobacterium nucleatum* promotes chemoresistance to colorectal cancer by modulating autophagy. *Cell*. 2017;170:548–63.e16.
- Huang X, Hong X, Wang J, Sun T, Yu T, Yu Y, et al. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues *Fusobacterium nucleatum*-induced colorectal tumorigenesis. *EBioMedicine*. 2020;61:103037.
- Ferrara A, Lewis JD, Quesenberry CP, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. *Diabetes Care*. 2011;34:923–9.
- Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. *Lancet Oncol*. 2016;17:475–83.
- Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. *Ann Oncol*. 2016;27:2184–95.
- Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, et al. Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial. *Clin Cancer Res*. 2019;25:6967–75.
- Miranda VC, Braghiroli MI, Faria LD, Bariani G, Alex A, Bezerra Neto JE, et al. Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer. *Clin Colorectal Cancer*. 2016;15:321–8.e1.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) method. *Methods*. 2001;25:402–8.
- Johnson S, Chen H, Lo P-K. In vitro tumorsphere formation assays. *Bio Protoc*. 2013;3:e325.
- Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinforma*. 2013;14:7.
- Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, et al. High accumulation of metformin in colonic tissue of subjects with diabetes or the metabolic syndrome. *Gastroenterology*. 2018;154:1543–5.
- Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. *Nat Rev Cancer*. 2018;18:669–80.

27. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. *Nat Rev Clin Oncol*. 2011;8:97–106.
28. Machado MV, Diehl AM. Hedgehog signalling in liver pathophysiology. *J Hepatol*. 2018;68:550–62.
29. Huang J, Liu H, Sun T, Fang JY, Wang J, Xiong H. Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells. *Clin Sci (Lond)*. 2019;133:483–95.
30. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136:215–33.
31. Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor- κ B, and up-regulating expression of microRNA-21. *Gastroenterology*. 2017;152:851–66.e24.
32. Psathas JN, Thomas-Tikhonenko A. MYC and the art of microRNA maintenance. *Cold Spring Harb Perspect Med*. 2014;4. <https://doi.org/10.1101/cshperspect.a014175>.
33. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science*. 2013;342:967–70.
34. Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. *Nat Rev Microbiol*. 2019;17:156–66.
35. Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. *Science*. 2017;358:1443–8.
36. Zhao J. Cancer stem cells and chemoresistance: The smartest survives the raid. *Pharm Ther*. 2016;160:145–58.
37. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell*. 2015;16:225–38.
38. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. *Proc Natl Acad Sci USA*. 2015;112:1839–44.
39. MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. *Cancer Lett*. 2018;428:117–26.
40. Han D, Yu T, Dong N, Wang B, Sun F, Jiang D. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. *J Exp Clin Cancer Res*. 2019;38:289.
41. Wang X, Yang Y, Huycke MM. Commensal bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect. *Gut*. 2015;64:459–68.
42. Sahu U, Choudhury A, Parvez S, Biswas S, Kar S. Induction of intestinal stemness and tumorigenicity by aberrant internalization of commensal non-pathogenic *E. coli*. *Cell Death Dis*. 2017;8:e2667.
43. Liu QQ, Li CM, Fu LN, Wang HL, Tan J, Wang YQ, et al. Enterotoxigenic *Bacteroides fragilis* induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B. *Gut Microbes*. 2020;12:1788900.
44. Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the hedgehog pathway in cancer: current evidence and future perspectives. *Cells*. 2019;8. <https://doi.org/10.1080/19490976.2020.1788900>.
45. Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. *Nat Med*. 2018;24:1919–29.
46. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat Med*. 2017;23:850–8.
47. Shin N-R, Lee J-C, Lee H-Y, Kim M-S, Whon TW, Lee M-S, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut*. 2014;63:727–35.
48. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. *Diabetes Care*. 2017;40:54–62.
49. Cabreiro F, Au C, Leung K-Y, Vergara-Irigaray N, Cochemé HM, Noori T, et al. Metformin retards aging in *C. elegans* by altering microbial folate and methionine metabolism. *Cell*. 2013;153:228–39.

AUTHOR CONTRIBUTIONS

X-L Hong performed the experiments, analyzed the data, and wrote the manuscript; T-C Yu performed the experiments; X-W Huang performed the bioinformatics analyses; J-L Wang planned the project, and participated in data analysis, data interpretation; T-T Sun, T-T Yan, C-B Zhou, H-M Chen, and W-Y Su performed the experiments; H Xiong and W Du conceived, designed, and planned the project, and participated in experimental design, data analysis, data interpretation, and manuscript writing.

FUNDING

This work was supported by grants from the Shanghai Municipal Education Commission—Gaoyuan and Gaofeng Clinical Medicine Grant (No: 20191907), the Major health science and technology projects in Zhejiang Province (No: WKJ-ZJ-2217), and medical research project of Science and Technology Innovation Action Plan in Shanghai (No: 21Y11912800).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Mouse experiments were conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41416-022-02044-6>.

Correspondence and requests for materials should be addressed to Wan Du or Hua Xiong.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022